MedTrace Logo

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

NCT00122356 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2013-03-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long alendronate treatment is needed.

Conditions

Interventions

DRUG

Alendronate sodium

70mg tablets, once weekly

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Barwon Health

    lead OTHER_GOV

Principal Investigators

  • Karen White · Barwon Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2013-02-28
Completion
2013-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122356 on ClinicalTrials.gov